Q1 2025 EPS Estimates for KalVista Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Research analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of KalVista Pharmaceuticals in a research note issued on Monday, July 15th. HC Wainwright analyst A. Fein now expects that the specialty pharmaceutical company will post earnings per share of ($0.90) for the quarter, down from their prior estimate of ($0.57). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.38) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.54) EPS, FY2026 earnings at ($2.25) EPS, FY2027 earnings at ($1.39) EPS, FY2028 earnings at ($0.37) EPS and FY2029 earnings at $0.62 EPS.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.29).

Separately, Needham & Company LLC reduced their price target on shares of KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating for the company in a report on Friday, July 12th.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $14.20 on Wednesday. KalVista Pharmaceuticals has a fifty-two week low of $7.21 and a fifty-two week high of $16.88. The firm has a fifty day moving average price of $12.08 and a two-hundred day moving average price of $12.53. The company has a market cap of $599.07 million, a PE ratio of -4.18 and a beta of 0.91.

Insider Buying and Selling

In related news, insider Edward P. Feener sold 8,088 shares of the stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $95,114.88. Following the completion of the sale, the insider now owns 72,858 shares in the company, valued at approximately $856,810.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,465 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $11.53, for a total value of $86,071.45. Following the completion of the sale, the chief executive officer now owns 224,547 shares in the company, valued at approximately $2,589,026.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Edward P. Feener sold 8,088 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $95,114.88. Following the completion of the sale, the insider now owns 72,858 shares of the company’s stock, valued at approximately $856,810.08. The disclosure for this sale can be found here. Insiders sold 37,512 shares of company stock worth $439,424 in the last quarter. 12.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KALV. Tower Research Capital LLC TRC boosted its stake in shares of KalVista Pharmaceuticals by 28.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock valued at $43,000 after purchasing an additional 768 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $49,000. AJOVista LLC bought a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at about $60,000. EntryPoint Capital LLC bought a new position in KalVista Pharmaceuticals during the 1st quarter worth approximately $92,000. Finally, Entropy Technologies LP bought a new position in KalVista Pharmaceuticals during the 1st quarter worth approximately $121,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.